1don MSN
Pfizer says experimental breast cancer drug cuts risk of disease worsening in mid-stage trial
March 17 (Reuters) - Pfizer said on Tuesday its experimental combination reduced the risk of disease progression or death by ...
Pfizer expands oncology and immunology pipeline strength New therapies show progress in clinical development Focus shifts ...
Pfizer Inc (NYSE:PFE) develops medicines and vaccines across multiple therapeutic areas, contributing to the S&P 500 ...
Zacks Investment Research on MSN
Pfizer Inc. (PFE) is attracting investor attention: Here is what you should know
Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares ...
The clearance in China comes weeks after Pfizer acquired rights to the therapy. Elsewhere, Alnylam is looking for “novel” cardiovascular targets and investors sold off Helus shares.
Right now, Pfizer's dividend payout ratio is above 100%. That suggests the dividend comes with some risk, which is true.
Could “TrumpRx” be the prescription for lower drug prices? President Donald Trump announced a landmark deal with Pfizer to cut drug prices and sell medications on TrumpRx, a direct-to-consumer federal ...
Pfizer (PFE) looks undervalued at 8–9x forward earnings with a ~7% yield; see how Seagen, cost cuts and the pipeline could ...
The company incurred a loss in its most recent quarterly results.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results